Monday, April 27
2:00 pmRegistration Open
3:00 pmOrganizer's Welcome Remarks
Capital Markets Readiness in the Next Wave of Digital Health
Christina Roupas – Partner in Charge - Chicago, Cooley
As digital health companies navigate tighter markets and heightened scrutiny, capital markets readiness has become a strategic imperative. This talk highlights what investors expect from healthtech companies positioning for growth, liquidity, or exit.
Cooley Capital Call @ DHIS
Roy Moran – Partner, Cooley, Emcee and Judge
Finalists:
Tony Blau, CEO and Founder, All4Cure
Smita Sawant, CEO, Azodha
Idara Umoh, Founder and President, ClariVue Health
Charles Brown, CEO, Crosswalk Health
Alodeep Sanyal, Co-founder and CEO, LifePlus
Laurence Klein, CEO, Nuvo
Robert Bunn, President and Founder, Ultrasound AI
Buy or Build? Strategic Paths for Adopting Generative AI in Healthcare
Caitlin Donovan, Partner, General Catalyst
Healthcare organizations face pivotal decisions on how to incorporate generative AI into clinical operations, patient engagement, administrative workflows, and beyond. This session, will explore the strategic decision-making process behind partnering with vendors, building internal capabilities, or pursuing hybrid models—highlighting the operational, financial, and long-term implications of each path.
If Your Data Sucks, Your AI Will Too. UNsuck it!5:05 pmTransition to Breakout Sessions
Before You Cut Paid Media… Fix These 10 Things FirstPaid media is often dismissed in MedTech, HealthTech, and complex B2B—not because it can’t work, but because it’s judged without the right foundations. Ally Quilty and Nick Kowalczyk walk through the 10 systems needed for paid media to drive pipeline and ROI, from targeting and compliant messaging to CRM setup and offline conversion tracking. Attendees gain a clear framework to diagnose what’s truly limiting performance.
Digital Health Investment: Headwinds and Opportunities Driven by the Evolving Regulatory EnvironmentThis session will examine key regulatory considerations shaping digital health business models, including strategic partnerships with providers, payers, and pharmaceutical companies; evolving approaches to privacy, patient consent, and access to health information; and the FDA’s shifting oversight of generative AI, including “wellness” products and clinical decision support. The discussion will also highlight emerging government initiatives such as TEMPO and ACCESS and their implications for innovation, data sharing, and scalable healthcare growth.
5:40 pmWelcome Networking Reception
7:10 pmClose of Day
Tuesday, April 28
7:30 amRegistration and Morning Coffee
8:30 amOrganizer's Welcome Remarks
Capital at the Crossroads: Services vs. Tech in Healthcare Investment
Alyssa Reisner, Partner, Ventures, CVS Health
Crucial decisions are being made as investors consider the balance between tech-driven scalability and the operational realities of services-based healthcare. This panel will unpack where capital is flowing now, how investors are evaluating risk in a high-cost environment, and what the next cycle means for founders building at the intersection of care delivery, infrastructure, and technology.
10:20 amNetworking Coffee Break
Innovating beyond the City Limits: The Future of Rural Health
Liana Guzman, CEO, Folx Health
Rural health systems are confronting intensifying challenges—from workforce shortages and hospital closures to rising chronic disease and persistent digital infrastructure gaps. Yet new models of virtual care, remote monitoring, data-driven care coordination, and tech-enabled community partnerships are creating real opportunities for transformation. This session explores what sustainable, tech-powered innovation looks like outside major metro markets.
12:00 pmNetworking Luncheon & Breakout Roundtables
Predicting and Impacting Software Company Valuations
Brian Molk, Managing Director, US Lead for Product and Technology Strategy and Due Diligence, KPMG
The deal market for software companies is changing in predictable and surprising ways. While some company’s valuations will skyrocket, many will watch valuations go down, or stay depressed. The outcome is not entirely out of your control. Whether looking at a software target or evaluating your own company for exit, this presentation highlights how you can determine which direction a company’s valuation is likely to head, how to evaluate that during a due diligence and how to rapidly improve.
The Business of Longevity and Healthspan Through Digital
Stephen Klasko, Executive in Residence, General Catalyst
As longevity science meets digital health, new models are emerging that use continuous monitoring, AI-driven insights, and virtual-first prevention to extend healthspan at scale. This session explores what’s evidence-based, what’s commercially viable, and how technology can bring longevity innovation into everyday care.
Where is the strongest scientific, clinical, and digital biomarker evidence emerging in longevity and aging?
Which technology-enabled business models—virtual clinics, remote monitoring programs, AI-driven diagnostics, consumer platforms—are gaining real traction?
How should companies balance consumer demand with scientific validation, data privacy, and regulatory oversight?
How are investors evaluating digital-first longevity solutions in a space with limited long-term outcomes data?
What partnerships between biotech, healthcare systems, and digital health companies show the greatest promise?
How can longevity innovations integrate into mainstream preventive and chronic care pathways through digital tools and data-driven workflows?
2:40 pmNetworking Refreshment Break
Nobody Has a Map for This: Building Digital Health Teams in the Age of Agentic AI
Oncology AI That's Working — Clinically and Commercially
Eric Horler, President & CEO, AIQ Solutions Inc
AIQ is a Madison-based start-up enabling individuals with metastatic cancer to live better lives and see more grandchildren birthdays. AIQ provides software-enabled services that help oncologists optimize therapy. Clinical studies demonstrate that AIQ's reports add utility in over 80% of cases and influence treatment decisions in 65% of cases, with potential drug cost reductions exceeding $100,000 per patient. With an approved CPT billing code and strong product-market fit, AIQ is poised for rapid growth.
The Digitally-Enabled Health System: Rebuilding Care Delivery for a Hybrid Future
Molly McColl, Vice President, Virtual Health and Clinical Transformation, Advocate Health
Beyond the Buzz: What's Next for Generative AI in Health and Care?
Michelle Snyder, Partner, McKesson Ventures
The initial hype cycle has created both momentum and confusion around generative AI’s real potential in healthcare. This forward-looking conversation will examine emerging use cases with staying power, the infrastructure required to support them, and the guardrails necessary to ensure transparency, trust, and measurable impact across clinical, research, and operational domains.
5:05 pmClosing Networking Reception
6:05 pmClose of Summit
CONFERENCE CONTENT
Ben Lakin, PhD
Chief Executive Officer
(+1) 781-972-5454
blakin@cambridgeinnovationinstitute.com
Jason Green
Senior Conference Director
jgreen@cambridgeinnovationinstitute.com
PARTNERING & SPONSORSHIP
Brian Caine
Manager, Strategic Partnerships
Venture, Innovation & Partnering (VIP) Event Series
(+1) 908-809-0946
bcaine@cambridgeinnovationinstitute.com
SVB Healthcare Investment Landscape Overview 
Introduction to the Recipient of the 2026 Digital Healthcare Innovator Award
Introduction to the Executive Keynote
The AI-Powered EMR Connecting Providers, Pharmacies, and Patients
Killing the Security Tax: Scaling HealthTech Without the Headcount
Where Guidelines End and the Art of Care Begins. Why AI startups Fail to Scale